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OBJECTIVES We sought to evaluate the impact of intravenous antagonists of the platelet IIb/IIIa receptor
on the survival of patients undergoing percutaneous coronary interventions (PCIs).
BACKGROUND Several trials have shown that intravenous antagonists of the platelet glycoprotein (GP)
IIb/IIIa receptor reduce the incidence of myocardial infarction (MI) and composite cardiac
outcomes (death, MI, or revascularization) in patients undergoing PCI. However, individual
studies have not had adequate power to examine differences in mortality.
METHODS We performed a meta-analysis of 19 randomized, placebo-controlled trials (20 comparisons,
n  20,137). Death was the primary outcome. Secondary outcomes included MI, composite
cardiac outcomes, and major bleeding.
RESULTS Mortality was significantly reduced at 30 days (risk ratio [RR] 0.69 [95% confidence interval
[CI] 0.53 to 0.90]), at six months (RR 0.79 [95% CI 0.64 to 0.97]), and including longer
follow-up (RR 0.79 [95% CI 0.66 to 0.94]), with no significant between-study heterogeneity.
The relative risk reduction was largely similar in trials of patients with or without acute
myocardial infarction (AMI), in trials continuing or discontinuing heparin after the
procedure, and in trials using stents or another PCI as the intended primary procedure.
Myocardial infarction and composite outcomes were significantly reduced (p  0.001 for all)
at 30 days and six months. Major bleeding was significantly increased only in trials where
heparin infusion was continued after the procedure (RR 1.70 [95% CI 1.36 to 2.14]),
although there was no excess bleeding when heparin was discontinued (RR 1.02 [95% CI 0.85
to 1.24]).
CONCLUSIONS In patients undergoing PCI, GP IIb/IIIa receptor antagonists confer a significant and
sustained decrease (20% to 30%) in the risk of death. (J Am Coll Cardiol 2003;41:26–32)
© 2003 by the American College of Cardiology Foundation
Platelet glycoprotein (GP) IIb/IIIa receptor antagonists
significantly reduce the incidence of myocardial infarction
(MI) and the need for revascularization among patients who
undergo percutaneous coronary interventions (PCIs) (1–8).
However, previous trials (1–6) and meta-analyses (7,8)
could not conclusively determine whether these drugs also
significantly reduce mortality, per se. Studies of patients
with acute coronary syndromes where PCIs were performed
only selectively and at the physician’s discretion show no
significant survival benefit (9), except for diabetics (10). It
remains unclear whether platelet GP IIb/IIIa receptor
antagonists can reduce mortality in patients committed to
undergo PCI.
Several additional pertinent trials have been conducted
recently, especially in acute myocardial infarction (AMI)
patients (11–15). Therefore, we performed a comprehensive
meta-analysis of 20 randomized comparisons to clarify the
effect of intravenous GP IIb/IIIa receptor antagonists on
mortality in patients undergoing PCI with various clinical
backgrounds.
METHODS
Eligibility and search strategy. The meta-analysis in-
cluded randomized trials comparing any type of intravenous
GP IIb/IIIa receptor antagonist (e.g., abciximab, eptifi-
batide, tirofiban, lamifiban) against placebo or no treatment
in patient populations where all subjects underwent PCI
(elective, urgent/emergent). Eligible PCIs included percu-
taneous transluminal coronary angioplasty (PTCA), stent
placement, and atherectomy (directional, rotational, or ex-
cimer laser). We only targeted comparisons where PCI
choices were the same in the compared arms. We allowed
different dosing of concomitant heparin. We excluded trials
where only selected patients eventually underwent PCI,
because the decision for PCI subsequent to randomization
would be influenced by the clinical course.
We identified eligible trials in MEDLINE, EMBASE,
and the Cochrane Controlled Trials Registry (last search
April 2002) using the key words: abciximab, eptifibatide,
tirofiban, and lamifiban, combined with key words sug-
gested for identifying controlled trials. Bibliographies of
articles and reviews were screened.
Outcomes. The primary outcome was death at 30 days and
6 months. We also examined available data on longer
follow-up (one to three years). Secondary outcomes in-
cluded MI and a composite of major adverse cardiac events
(death, MI, or revascularization) at 30 days and 6 months.
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Safety outcomes included major bleeding by the Thrombol-
ysis in Myocardial Infarction (TIMI) criteria, or, alterna-
tively, severe/moderate bleeding by the Global Utilization of
Streptokinase and TPA for Occluded arteries (GUSTO)
criteria, and intracranial hemorrhage.
Data. We systematically extracted information on study
design and reported trial quality (16), participant character-
istics, and outcomes, as mentioned. In trials with more than
two arms, arms using different dosing schedules were
merged to avoid duplicating the control arm. Two investi-
gators (Drs. Karvouni and Katritsis) extracted data indepen-
dently, discussed discrepancies, and reached a consensus
with a third independent investigator (Dr. Ioannidis).
Analysis. Intention-to-treat analyses use risk ratios (RRs)
(relative risk reductions  1  RR). Odds ratios were
similar (data not shown). Risk differences are also provided
for death and major bleeding. Heterogeneity was assessed
with the chi-squared–based Q statistic (significant for p 
0.10). We used both fixed and random effects models. In the
absence of between-study heterogeneity, these models co-
incide; otherwise, random effects provide wider confidence
intervals (CIs) (17).
Subgroup analyses were performed for mortality accord-
ing to: 1) patient population (AMI vs. non-AMI); 2)
intended PCI; 3) type of GP IIb/IIIa receptor antagonist;
and 4) heparin use post-PCI. Heterogeneity between sub-
groups was assessed with the Q statistic.
Bias diagnostics evaluated whether results of small versus
large studies (18) and early versus late trials (19) differed.
No bias was detected (data not shown). Analyses were
conducted using Meta-Analyst (Joseph Lau, Boston, Mas-
sachusetts) and SPSS (SPSS Inc., Chicago, Illinois). The
p values are two-tailed.
RESULTS
Eligible studies. Nineteen trials (1–6,11–15,20–36) with
20 pertinent comparisons (n  20,137) were eligible (Table
1). One trial (14) had four arms, resulting in two pertinent
comparisons (stent placement vs. PTCA). All but four trials
(12,15,25,26) were multicenter. Most trials used abciximab.
Four trials used eptifibatide and two trials used tirofiban.
Stent placement was the initial procedure in 7 comparisons
(12–14,20,23,26,29), and PTCA or atherectomy in 13. Five
studies (six comparisons) (11–15) targeted AMI patients
exclusively. Acute myocardial infarction patients comprised
also about one-third of the Evaluation of IIb/IIIa platelet
receptor antagonist 7E3 in Preventing Ischemic Complica-
tions (EPIC) and Randomized Efficacy Study of Tirofiban
for Outcomes and REstenosis (RESTORE) patients (1,35).
One trial (15) used alternate randomization, whereas all
others were truly randomized, although the details on the
randomization were provided infrequently (1,14,28,29). Al-
location concealment was explicitly described in eight trials
(1,4,20,23,24,26,28,29), and withdrawals in nine trials
(1,4,6,12,20,23,26,29,34). All but two trials (12,26) were
double-masked.
Meta-analysis. Overall death rates in treatment versus
control arms were 105/11,676 (0.90%) versus 116/8,461
(1.37%) at 30 days, 172/8,686 (1.98%) versus 176/6,965
(2.53%) at six months, and 252/78,686 (2.90%) versus
234/6,965 (3.36%) at longer follow-up (Fig. 1). Glyco-
protein IIb/IIIa receptor antagonists conferred a significant
31% relative reduction in 30-day mortality (95% CI 10% to
47%, p  0.006 for fixed effects; p  0.008 for random
effects; no between-study heterogeneity). A relative risk
reduction of 21% was maintained at six months (95% CI 3%
to 36%, p  0.028 for fixed effects; 95% CI 0% to 37%, p 
0.048 for random effects) and when longer follow-up was
considered (21%; 95% CI 6% to 34%, p  0.008 for fixed
effects; 95% CI 3% to 36%, p  0.023 for random effects).
The respective absolute decrease was 0.31% (95% CI 0.05%
to 0.57%) at 30 days, 0.46% (95% CI 0.05% to 0.88%) at six
months, and 0.59% (95% CI 0.10% to 1.07%) including
long-term follow-up by fixed effects. Random effects were
similar (data not shown). No single trial showed statistically
significant mortality reductions, but most showed trends
favoring the experimental arms (Fig. 1).
The benefit was similar in patients with and without
AMI (Table 2). No clear effect was observed in two trials,
including both AMI and non-AMI patients, but the CIs
were large. Overall 30-day mortality rates in the control
arms were 3.1% (95% CI 2.4% to 4.1%) in AMI trials, 1.1%
(95% CI 0.7% to 1.8%) in trials with both AMI and
non-AMI patients, and 0.9% (95% CI 0.6% to 1.2%) in
non-AMI trials. The six-month mortality rates were 4.8%
(CI 3.8% to 6.0%), 2.2% (CI 1.6% to 3.0%), and 1.6%
(CI 1.2% to 2.1%), respectively. The survival benefit was
similar in trials where stent placement was the primary
procedure and in trials continuing versus discontinuing
heparin. No mortality reduction was observed with tirofiban
at either time point, but the CIs were large (Table 2).
Glycoprotein IIb/IIIa receptor antagonists significantly
decreased (p  0.001) MI and composite outcomes both at
30 days and 6 months (Table 3). There was a modest
increase in the risk of major bleeding (random effects risk
difference 0.68%, 95% CI 0.05% to 1.40%), with signifi-
cant between-study heterogeneity. The findings were not
different in subgroups defined by AMI, type of PCI, and
type of agent (data not shown). The heterogeneity disap-
peared when we separated trials based on whether heparin
had been continued or not after the procedure. Excess
bleeding was observed only in trials continuing heparin
Abbreviations and Acronyms
AMI  acute myocardial infarction
CI  confidence interval
GP  glycoprotein
MI  myocardial infarction
PCI  percutaneous coronary intervention
PTCA  percutaneous transluminal coronary angioplasty
RR  risk ratio
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Table 1. Eligible Trials
Trial
(Ref.) n PCI AMI (%) [Time]
Heparin
Post-PCI
Male
(%)
Mean Age
(yrs)
Past Medical History (%)
DM HTN MI PCI CABG
Abciximab
RAPPORT (11) 483 PTCA or DCA 100 [12 h] Yes 72 61 22 48 19 14
ADMIRAL (13) 300 Stenting 100 [12 h] Yes 82 61 18 38 11 14 12
CADILLAC (14) 2,082 PTCA/stenting 100 [12 h] No 73 60 17 48 14 11 2
EPIC (1–3) 2,099 PTCA or DCA 30 [12 h] Yes 72 61 24 55 38 22 15
EPILOG (4,5) 2,792 PTCA or DCA 0 No 72 60 23 ND 27 ND 13
EPISTENT (20–22) 1,603 Stenting 0 No 75 59 20 53 51 ND 9
CAPTURE (6) 1,266 PTCA 0 Yes 73 61 14 42 40 13 3
ERASER (23) 225 Stenting Negligible* No 79 59 14 50 ND 14 ND
Petronio et al. (15) 89 PTCA 100 [24 h] No 65 60 18 ND 10 ND 1
Simoons et al. (24) 60 PTCA 0 No 73 61 ND ND 42 15 4
Kini et al. (25) 100 HSRA 0 No 75 64 26 44 18 ND 15
Tamburino et al. (26) 107 Stenting 0 No 87 62 27 34 67 ND ND
ISAR-2 (12) 401 Stenting 100 Yes 76 60 15 64 ND 7 4
Eptifibatide
IMPACT (27) 150 PTCA or DCA 0 Yes 75 61 21 53 43 39 17
IMPACT-II (28) 4,010 Various† 3 [24 h] No 75 61 23 54 41 30 16
ESPRIT (29–32) 2,064 Stenting 0 No 73 62 20 59 32 23 10
Harrington et al. (33) 73 Various† 0 No 75 60 29 68 45 ND 26
Tirofiban
RESTORE (34,35) 2,141 PTCA or DCA 32 [72 h] No 72 59 20 55 34 21 7
Kereiakis et al. (36) 93 PTCA 0 Yes 82 59 24 53 47 23 15
*14% of patients had unstable angina or AMI within 48 h. †PTCA, DCA, HSRA (also excimer laser in IMPACT-II).
AMI  acute myocardial infarction; CABG  coronary artery bypass graft; DCA  directional coronary atherectomy; DM  diabetes mellitus; HSRA  high-speed rotational atherectomy; HTN  hypertension; MI  myocardial
infarction; ND  no data; PCI  percutaneous coronary intervention (originally intended procedure[s] in each trial); PTCA  percutaneous transluminal coronary angioplasty.
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(RR 1.70 [95% CI 1.36 to 2.14] vs. RR 1.02 [95% CI 0.85
to 1.24] in those stopping heparin). The risk of hemorrhagic
stroke was not increased (Table 3).
DISCUSSION
Intravenous GP IIb/IIIa receptor antagonists confer a def-
inite survival benefit among patients who undergo PCI. A
20% to 30% relative risk reduction is clinically important
and complements our insight about the previously well-
documented effects of these agents in reducing the risk of
MI and composite cardiac end points (7). The survival
benefit is clearly observed at 30 days and persists at
long-term follow-up.
We observed no significant differences in the magnitude
of the treatment effect in subgroup analyses according to
clinical setting (AMI or non-AMI), type of intervention
(stent vs. other), and timing of heparin administration. No
survival benefit was documented with tirofiban. It is un-
known whether this might be due to the relatively low
tirofiban dose employed. Both abciximab and eptifibatide
showed considerable survival benefits, the latter missing
formal statistical significance, probably due to smaller num-
bers of randomized subjects.
In the overall meta-analysis, the number of patients
needed to treat to save one life at 30 days, six months, and
long-term follow-up was 320, 220, and 170, respectively.
However, AMI patients are at higher risk than non-AMI
patients for death and other adverse cardiac events. There-
fore, the absolute benefit (risk difference) may actually be
larger in high-risk AMI patients than in low-risk patients
undergoing elective PCI, where the mortality risk is very
low. The absolute benefit may be small and cost-
effectiveness may be questionable in patients at very low risk.
Although hemorrhagic stroke was not a concern, we
documented an excess of major bleeding with significant
between-study heterogeneity. Heterogeneity may reflect
whether heparin is continued or not after PCI. Heparin is
well known to increase the bleeding risk. When heparin was
discontinued after the procedure, there was no excess major
bleeding, and the therapeutic effect remained undiminished.
Table 2. Subgroup Analyses for Mortality
30 Days 6 Months
No. of Studies (n)
20 (20,137)*
RR (95% CI)
0.69 (0.53–0.90)*
No. of Studies (n)
14 (15,651)*
RR (95% CI)
0.79 (0.64–0.97)*
Population
AMI 6 (3,355) 0.69 (0.45–1.05) 6 (3,355) 0.76 (0.55–1.05)
Mixed 2 (4,240) 0.95 (0.54–1.68) 2 (4,240) 0.97 (0.65–1.44)
Non-AMI 12 (12,542) 0.59 (0.39–0.89) 6 (8,056) 0.71 (0.49–1.03)
Procedure
Stent 7 (5,736) 0.69 (0.43–1.09) 7 (5,736) 0.70 (0.49–1.01)
Other 13 (14,401) 0.70 (0.51–0.96) 7 (9,915) 0.84 (0.65–1.09)
Post-procedure
Heparin 7 (4,791) 0.72 (0.47–1.09) 5 (4,548) 0.83 (0.60–1.13)
No heparin 13 (15,346) 0.68 (0.49–0.95) 9 (11,103) 0.77 (0.58–1.01)
Agent
Abciximab 14 (11,606) 0.69 (0.51–0.94) 12 (11,446) 0.77 (0.61–0.96)
Tirofiban 2 (2,234) 1.05 (0.42–2.61) 1 (2,141) 1.27 (0.65–2.48)
Eptifibatide 4 (6,297) 0.60 (0.33–1.06) 1 (2,064) 0.56 (0.24–1.34)
There was no statistically significant heterogeneity in any case, and random effects estimates were similar (data not shown).
*Refers to all patients.
AMI  acute myocardial infarction; CI  confidence interval; RR  risk ratio (fixed effects).
Table 3. Secondary Outcomes
Outcome
No. of
Studies (n)
Total Events/Patients (%)
RR (95% CI)Active Treatment Control Arm
MI (30 days) 20 (20,137) 537/11,676 (4.6) 585/8,461 (6.9) 0.63 (0.56–0.70)
MI (6 months) 13 (15,250) 481/8,485 (5.7) 550/6,765 (8.1) 0.67 (0.60–0.76)
Composite* (30 days) 20 (20,137) 926/11,676 (7.9) 978/8,461 (11.6) 0.65 (0.59–0.72)
Composite* (6 months) 13 (15,250) 1,817/8,485 (21.4) 1,624/6,765 (24.0) 0.85 (0.80–0.90)
Major bleeding 20 (20,137) 531/11,676 (4.6) 273/8,461 (3.2) 1.26 (1.09–1.46)
Hemorrhagic stroke† 18 (19,612) 14/11,373 (0.1) 10/8,239 (0.1) 0.89 (0.46–1.72)
*The composite outcome includes death, myocardial infarction (MI), or revascularization. For the last component, we used any
target vessel revascularization, except for studies where this was not a trial outcome, in which case, urgent or all revascularizations
were counted. †The ADMIRAL and ERASER trials provided no data on hemorrhagic stroke. There was no statistically
significant heterogeneity, and random effects estimates were very similar (data not shown), except for the composite outcome at
30 days (P  0.04 for heterogeneity, random effects RR 0.66 [95% CI 0.57–0.75]) and major bleeding (P  0.08 for
heterogeneity, random effects RR 1.19 [95% CI 0.96–1.48]).
CI  confidence intervals; RR  risk ratio, based on fixed effects calculations.
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Figure 1. Mortality at 30 days (A), six months (B), and longer follow-up (C). Risk ratios and 95% confidence intervals are shown for each study and for
the random effects summary (17). P  PTCA; S  stenting. Continued on next page.
Subgroup analyses should be interpreted cautiously, but the
data suggest that major bleeding does not countermatch the
survival benefits and may not be a problem if heparin is
promptly discontinued.
There has been no demonstrable overall mortality reduc-
tion in trials of acute coronary syndromes where only
selected patients undergo PCI (7,10), with the exception of
diabetics (10). Actually the largest mortality reduction in
these trials occurred for diabetics who also underwent PCI
eventually (10). The survival benefit of intravenous GP
IIb/IIIa receptor antagonists may be linked to the PCI, per
se, and the consequences of the procedure-related intimal
damage and revascularization. In this meta-analysis, no
separate data were available to address whether the benefi-
cial effect on survival was different in diabetics versus
nondiabetics. However, the proportion of diabetics was
limited and unlikely to explain all of the observed mortality
reduction. Separate subgroup analyses focusing on high-risk
subjects (diabetics, subjects with high troponin levels) are
warranted, but subgroup differences should be interpreted
cautiously.
Conclusions. This meta-analysis provides adequate evi-
dence for using intravenous GP IIb/IIIa receptor antago-
nists during PCIs to reduce short- and long-term mortality,
but data should not be generalized to patients in whom no
PCI is contemplated.
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